Is Thymosin Alpha-1 Legal in Wisconsin?

HealthRX.com

No clear legal route to a Wisconsin pharmacy for thymosin alpha-1

Print or save as PDF

Key numbers

  • 1.6 mgItalian Zadaxin label dose per injection; no US-approved dose existsSource: fda.gov, as cited Nov 7, 2026
  • 1056 peopleHepatitis B trials: 5 trials with 1056 people found low-certainty evidence of fewer serious adverse eventsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 4 yes and 17 noFDA advisory committee vote on adding thymosin alpha-1 to the compounding bulks list, December 2024Source: fda.gov, as cited Nov 7, 2026
  • 17 million dosesZadaxin doses given after marketing, as reported by authors tied to the makerSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / None. No US marketing application exists for thymosin alpha-1 [1]
  • FDA list for state-licensed pharmacies / Not on it, and in none of the three nomination categories [2]
  • FDA list for outsourcing facilities / Category 3, 'nominated without adequate support' [4]
  • FDA advisory committee / Voted 4 yes, 17 no on both the free base and the acetate, December 2024 [5]
  • October 2026 HHS peptide policy / Does not include thymosin alpha-1 [6]
  • WADA Prohibited List / Not named on the 2026 List [7]
  • Wisconsin law / Chapter 450 governs pharmacy licensure and does not name the peptide [3]
  • Approved outside the US / Italy, India and Hong Kong, per FDA; Zadaxin is the brand [1]

Is thymosin alpha-1 legal in Wisconsin?

The federal status does most of the work here. A Drugs@FDA search found no US application for thymosin alpha-1; FDA's December 2024 review notes four US orphan drug designations, which are a separate process from approval and not an approval [1]. The peptide is a 28-amino-acid immune modulator that augments T-cell function, sold outside the US as Zadaxin 1.6 mg injections [1].

On the Wisconsin side, Wis. Stat. ch. 450 sets out pharmacy licensure, including licensure for out-of-state pharmacies [3]. The chapter does not name thymosin alpha-1.

Can a Wisconsin pharmacy compound it?

For state-licensed pharmacies and physicians, thymosin alpha-1 appears in none of the three categories on FDA's interim policy list (updated May 14, 2026), and the category 1 policy of generally no action against compounders does not apply to it [2]. The peptide had been in category 2, the significant-safety-risk group, and moved to the 'nominated but withdrawn' table after the nominators withdrew [8]. FDA's stated concerns remain: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information the agency called 'inadequate ... to sufficiently understand the extent of any safety issues' [8].

On the separate list for outsourcing facilities, thymosin alpha-1 sits in category 3, 'nominated without adequate support' (list updated March 21, 2025) [4].

Questions worth asking

Choose the questions you want to keep

What FDA's advisers concluded

FDA proposed that thymosin alpha-1 not be added to the list of bulk substances that may be used in compounding. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate [5]. Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access [5].

Thymosin alpha-1 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy (BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500) [6]. No FDA or HHS action allowing compounding of thymosin alpha-1 has been identified.

Is it approved anywhere else, or banned in sport?

FDA lists national authorizations in Italy (Zadaxin as an adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults 18 and older with compensated liver disease and viral replication) and Hong Kong; a 2014 company annual report claims approvals across parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, which FDA could not independently verify [1]. Two reviews by authors tied to the Zadaxin developer say 'over 35 countries' (2009) and 'more than 30 countries' (2007) [9][10]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, not a marketing approval [1].

WADA does not name thymosin alpha-1 on its 2026 Prohibited List [7]. WADA does name thymosin-beta-4 and derivatives such as TB-500 in S2.3, a different peptide [7].

What is known about dose and safety

There is no US-approved dose. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination; it states not for children, contraindicated in pregnancy and breastfeeding, and advises caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

Safety data are thin and partly company-linked. FDA's search of its adverse-event database in April 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 trial participants and over 17 million doses of Zadaxin given after marketing, with adverse experiences 'infrequent and mild' [1]. A 2026 Cochrane review of hepatitis B trials found thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1056 people; low-certainty evidence) and fewer non-serious events (RR 0.47, 95% CI 0.27 to 0.83; very low certainty) [11]. The same review rated the evidence for benefit as very low certainty, and the reviewers said they were 'not sure' it helps [11].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Which category does thymosin alpha-1 sit in on FDA's list for outsourcing facilities?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is thymosin alpha-1 legal in Wisconsin?
Wisconsin's pharmacy chapter covers licensure and does not name the peptide [3]. Thymosin alpha-1 is not FDA-approved, and FDA's category 1 no-action policy for state-licensed pharmacy compounding does not apply to it [1][2]. These facts do not establish a blanket Wisconsin ban.
Can a Wisconsin pharmacy fill a thymosin alpha-1 prescription?
Wisconsin chapter 450 sets licensure for pharmacies, including out-of-state pharmacies [3]. On the federal side, FDA's category 1 policy does not apply to thymosin alpha-1, it is in none of the categories on FDA's list for state-licensed pharmacies, and FDA proposed that it not be added to the compounding bulks list [2][5].
What did FDA's advisory committee decide about thymosin alpha-1?
On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate, against adding it to the compounding list [5].
Is thymosin alpha-1 approved in any country?
FDA lists authorizations in Italy, India and Hong Kong, with Zadaxin as the brand sold outside the US [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
Is thymosin alpha-1 banned in sport?
WADA does not name thymosin alpha-1 on its 2026 Prohibited List [7]. WADA names thymosin-beta-4 and TB-500, which are different peptides [7].
Is thymosin alpha-1 safe?
FDA's April 2024 search of its adverse-event database found zero reports [1]. Authors tied to the manufacturer describe adverse experiences as infrequent and mild across over 17 million doses, and a 2026 Cochrane review found it may have caused fewer serious adverse events than comparison treatments, based on low-certainty evidence [1][11].
Show all 11 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Wisconsin?